This is the second stock in our coverage of Pharma Sector. Dishman Pharmaceuticals is engaged in the business of synthetic chemistry research. It has organized the business in two streams: QUATs (quarternary ammonium compounds) & APIs (Marketable Molecules or MM Segment), and Contract Research and Manufacturing (CRAM).
This article was originally published on May 18, 2009.